NCT05410938

Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy

Triweekly Chemotherapy With Bevacizumab Versus Intraperitoneal Chemotherapy as Frontline Therapy in Advanced Ovarian Cancer

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 59 (actual)
• Sponsor: Far Eastern Memorial Hospital · Academic / Other
• Sex: Female
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The combination of paclitaxel and carboplatin is the standard first-line chemotherapy for ovarian cancer as recommended by the NCCN Guidelines for Epithelial Ovarian Cancer, and is conventionally given via intravenous route every three weeks. The addition of target therapy (bevacizumab) has shown to improve progression free survival but not overall survival. Several trials have also demonstrated a clinically significant survival advantage associated with intraperitoneal chemotherapy compared to intravenous chemotherapy, and the best outcomes are consistently seen for patients who have no residual disease. This study aims to compare triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.

Conditions

• Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Chemotherapy	Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab

Timeline

• Start date: 2022-06-06
• Primary completion: 2023-05-01
• Completion: 2023-05-01
• First posted: 2022-06-08
• Last updated: 2023-07-10

Locations

1 site across 1 country: Taiwan